Elicio Therapeutics (ELTX)
NASDAQ:ELTX
Total Valuation
Elicio Therapeutics has a market cap or net worth of $196.65M. The enterprise value is $182.64M.
Market Cap$196.65M
Enterprise Value$182.64M
Share Statistics
Elicio Therapeutics has 18,396,074 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,396,074
Owned by Insiders31.69%
Owned by Institutions6.03%
Financial Efficiency
Elicio Therapeutics’s return on equity (ROE) is -24.19 and return on invested capital (ROIC) is -201.00%.
Return on Equity (ROE)-24.19
Return on Assets (ROA)-1.53
Return on Invested Capital (ROIC)-201.00%
Return on Capital Employed (ROCE)-2.12
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count32
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elicio Therapeutics is ―. Elicio Therapeutics’s PEG ratio is 0.08.
PE Ratio―
PS Ratio0.00
PB Ratio74.50
Price to Fair Value74.50
Price to FCF-3.30
Price to Operating Cash Flow-4.42
PEG Ratio0.08
Income Statement
In the last 12 months, Elicio Therapeutics had revenue of 0.00 and earned -39.57M in profits. Earnings per share was -2.58.
Revenue0.00
Gross Profit-1.13M
Operating Income-37.71M
Pretax Income-39.57M
Net Income-39.57M
EBITDA-36.59M
Earnings Per Share (EPS)-2.58
Cash Flow
In the last 12 months, operating cash flow was -36.95M and capital expenditures -16.00K, giving a free cash flow of -36.97M billion.
Operating Cash Flow-36.95M
Free Cash Flow-36.97M
Free Cash Flow per Share-2.01
Dividends & Yields
Elicio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.79
52-Week Price Change106.77%
50-Day Moving Average10.02
200-Day Moving Average9.52
Relative Strength Index (RSI)48.63
Average Volume (3m)77.23K
Important Dates
Elicio Therapeutics upcoming earnings date is May 20, 2026, After Close (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Elicio Therapeutics as a current ratio of 2.38, with Debt / Equity ratio of 312.04%
Current Ratio2.38
Quick Ratio2.38
Debt to Market Cap0.09
Net Debt to EBITDA0.11
Interest Coverage Ratio-33.29
Taxes
In the past 12 months, Elicio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Elicio Therapeutics EV to EBITDA ratio is -3.22, with an EV/FCF ratio of -3.19.
EV to Sales0.00
EV to EBITDA-3.22
EV to Free Cash Flow-3.19
EV to Operating Cash Flow-3.19
Balance Sheet
Elicio Therapeutics has $18.56M in cash and marketable securities with $5.11M in debt, giving a net cash position of $13.46M billion.
Cash & Marketable Securities$18.56M
Total Debt$5.11M
Net Cash$13.46M
Net Cash Per Share$0.73
Tangible Book Value Per Share$0.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Elicio Therapeutics is $17.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.33
Price Target Upside62.11% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast17.36%